These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab. Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965 [TBL] [Abstract][Full Text] [Related]
7. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis. La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890 [TBL] [Abstract][Full Text] [Related]
8. The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis. Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Neubauer M; Quasthoff S Mult Scler; 2014 Aug; 20(9):1269-72. PubMed ID: 24493472 [TBL] [Abstract][Full Text] [Related]
10. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders. Balasa R; Bianca C; Septimiu V; Iunius S; Adina H; Sebastian A; Andreea R; Anca M; Smaranda M CNS Neurol Disord Drug Targets; 2018; 17(6):464-472. PubMed ID: 29968546 [TBL] [Abstract][Full Text] [Related]
11. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients. Teniente-Serra A; Grau-López L; Mansilla MJ; Fernández-Sanmartín M; Ester Condins A; Ramo-Tello C; Martínez-Cáceres E Autoimmunity; 2016 Jun; 49(4):219-28. PubMed ID: 26829210 [TBL] [Abstract][Full Text] [Related]
12. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245 [TBL] [Abstract][Full Text] [Related]
13. Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients. Johnson BH; Bonafede MM; Watson C CNS Drugs; 2015 Jun; 29(6):503-10. PubMed ID: 26113055 [TBL] [Abstract][Full Text] [Related]
14. Natalizumab discontinuation is associated with a rebound of cognitive impairment in multiple sclerosis patients. Iaffaldano P; Viterbo RG; Trojano M J Neurol; 2016 Aug; 263(8):1620-5. PubMed ID: 27260295 [TBL] [Abstract][Full Text] [Related]
15. Role of IL-17-producing lymphocytes in severity of multiple sclerosis upon natalizumab treatment. Bühler U; Fleischer V; Luessi F; Rezk A; Belikan P; Graetz C; Gollan R; Wolf C; Lutz J; Bar-Or A; Siffrin V; Zipp F Mult Scler; 2017 Apr; 23(4):567-576. PubMed ID: 27436357 [TBL] [Abstract][Full Text] [Related]